‘Injectable drugs give way to syrups, chewable tablets’

‘Injectable drugs give way to syrups, chewable tablets’

NEW DELHI : The next phase of the Indian pharmaceutical industry will be innovation in newer drugs and how drugs are delivered to patients, said Dr. Parag Sheth, regional medical director for Abbott India, in an interview. He cited examples such as smaller, chewable tablets and injectable formulations that turn into syrups. In addition, Abbott India plans to run a menopause awareness program in collaboration with hospitals across India following the findings of the latest survey, which indicated that more than 80% of women believe that menopause can affect personal well-being. of a woman due to little conscience. edited excerpts

How do you see the pharmaceutical sector in India?

India’s pharmaceutical industry has evolved considerably in recent years, and the country is now known as the world’s pharmacy. It is now the world’s largest provider of generic drugs and provides quality and affordable drugs and this is important for people to lead a healthy life not only in India but also outside of India.

The next phase will be innovation. We’re already into newer drugs and the way drugs are delivered to patients, that is, patient-friendly delivery. For example: from difficulty swallowing large tablets to smaller tablets, chewable tablets and something more compatible in terms of consumption. Another example is an injectable formulation to be converted to a syrup formulation or a syrup formulation to a ready-to-use syrup formulation so that the patient can mix water and consume it. Therefore, various innovative ways are being worked on. So I think India has made progress in delivering medicines to patients and is also looking at digital as a tool to reach people and target audiences. It’s not so much about discovering new molecules, but also about making sure people stick to medication for better impact and better disease control. Indian pharmaceuticals are going to evolve in both physical and digital space.

Would the recent cough syrup controversy affect the pharmaceutical sector in India?

I would not like to talk about this. But at Abbott, our top priority is to focus on quality. For us, the quality of medicines is paramount and therefore we feel that we are doing the right thing.

Tell us about Abbott India’s partnerships and expansion plans.

We continue to work with medical societies to ensure that people adhere to treatment compliance, as in most cases, people stop treatment in the middle. We have partnerships with the Thyroid Society of India, the Diabetic Society of India, etc. As a science-driven company, we continue to collaborate and expand. We have an R&D development that continues to explore new products and molecules.

Why did Abbot India conduct a survey dedicated to menopause and what were its results?

Women’s health care often tends to be ignored. Therefore, this menopause study was conducted in seven metropolitan cities and interviewed more than 1,200 participants, including the husband, daughter, and daughter-in-law of women in the 45-55 age group. The whole motto of the survey was to analyze what are the needs, perceptions and experiences of a woman facing menopause. As of now, the understanding of menopause among people is not very high. The findings indicate that more than 80% of the women felt that in addition to physical health symptoms, the woman also experiences problems in her work and social life and, of course, in family life. The woman is talking about it, but no one is discussing it with her. So, as a society, are we ready to talk about menopause? We want to start this conversation so that every woman can talk openly with her husband, colleagues, and friends. The surprising element of the study is that more than 90% of husbands said they would like their wives to talk to them about menopause directly and openly.

Do you plan any medical solutions or interventions based on the findings of the menopause survey?

At Abbott, we are already dedicated to women’s health care treatment therapies. The company generates many pharmaceutical interventions for women’s health in measurement, postpartum, menopause, pregnancy, IVF, infertility, etc., and has a very broad portfolio in women’s health. Our focus is to facilitate strong conversations between health professionals and women. Our goal is to encourage women to talk about menopause with their families. Our goal is to raise awareness about the issue.

See all corporate news and updates on Live Mint. Download The Mint News app for daily market updates and live trading news.

more less

Leave a Comment